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MW2 cells to SYTOX green, suggesting that they target bacterial membranes. Compound TBB showed 
synergistic activity with doxycycline and oxacillin against MRSA-MW2, and compounds PPT, NNC, 
GW4064, and PD198306 synergized with doxycycline, polymyxin-B, gentamicin, and erythromycin, 
respectively. The study demonstrates the utility of the multi-host approach with follow-up hit 
characterization for prioritizing anti-MRSA compounds for further evaluation. 
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Abstract: There is a significant need to combat the growing challenge of antibacterial drug resistance.
We have previously developed a whole-animal dual-screening platform that first used the nematode
Caenorhabditis elegans, to identify low-toxicity antibacterial hits in a high-throughput format. The hits
were then evaluated in the wax moth caterpillar Galleria mellonella infection model to confirm
efficacy and low toxicity at a whole animal level. This multi-host approach is a powerful tool
for revealing compounds that show antibacterial effects and relatively low toxicity at the whole
organism level. This paper reports the use of the multi-host approach to identify and validate five
new anti-staphylococcal compounds: (1) 4,4′,4”-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol(PPT),
(2) (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-
(1-methylethyl)-2-naphthalenyl cyclopropanecarboxylate dihydrochloride(NNC), (3) 4,5,6,7-tetrabromobe
nzotriazole (TBB), (4) 3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]
phenyl]ethenyl] benzoic acid(GW4064), and (5) N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-
methylphenyl)amino] benzamide(PD198306). The compounds reduced the severity of methicillin-resistant
Staphylococcus aureus (MRSA, strain MW2) infections in both C. elegans and G. mellonella and showed
minimal inhibitory concentrations (MICs) in the range of 2–8 µg/mL. Compounds NNC, PPT,
and TBB permeabilized MRSA-MW2 cells to SYTOX green, suggesting that they target bacterial
membranes. Compound TBB showed synergistic activity with doxycycline and oxacillin against
MRSA-MW2, and compounds PPT, NNC, GW4064, and PD198306 synergized with doxycycline,
polymyxin-B, gentamicin, and erythromycin, respectively. The study demonstrates the utility of the
multi-host approach with follow-up hit characterization for prioritizing anti-MRSA compounds for
further evaluation.
Keywords: antibiotic; high-throughput screening (HTS), MRSA; MIC; Caenorhabditis elegans; Galleria
mellonella
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1. Introduction
Staphylococcus aureus isolates that show resistance to methicillin (methicillin-resistant S. aureus,
MRSA) were first reported in the United Kingdom in 1961, and soon after, in other European countries,
Japan, Australia, and the US [1]. According to the Centers for Disease Control and Prevention (CDC),
in the US, there are more than 35,000 deaths and 90,000 severe cases of MRSA infection each year [2].
Vancomycin is typically the antibiotic of choice for treating serious Gram-positive bacterial infections,
including MRSA, but reports of vancomycin-resistant and vancomycin-intermediate S. aureus strains
are becoming more common [3].
Whole animal-based high-throughput screening (HTS) is a powerful tool for discovering
antibacterial compounds, including those that would otherwise be missed by traditional antibiotic
screens that report compounds that inhibit bacterial growth [4]. Our laboratory has developed a fully
automated HTS platform that utilizes the nematode Caenorhabditis elegans to identify compounds that
cure Staphylococcus aureus (MRSA) [5], Enterococcus faecalis [6], or Pseudomonas aeruginosa [7] infections
in C. elegans without showing frank host toxicity that results in the death of the nematodes. Since these
pathogens kill C. elegans, hit compounds are those that reduce C. elegans killing, resulting in an excess
of live worms compared to non-treated pathogen-infected nematodes. Highly toxic compounds do not
emerge as hits in the assay, because they kill the nematodes.
Here, we describe the coupling of the C. elegans HTS platform with a secondary screen that uses
MRSA infection of Galleria mellonella (wax moth) larvae (caterpillars) to validate the anti-staphylococcal
activity and low whole-animal toxicity of hit compounds at the whole-organism level [8]. In this study,
we used the dual-host approach to identify and validate five new anti-MRSA compounds, and report
follow-up characterization of their antibacterial and other properties.
2. Results
2.1. Identification of Compounds That Block the Ability of MRSA to Kill C. elegans
We previously reported that high throughput screening for compounds that reduce the ability of
MRSA to kill C. elegans yielded 185 hits from a total of 82,000 unique compounds tested [9]. Among the
185 hits, five compounds that prolonged C. elegans survival at a screening concentration of 2.86 µg/mL
(PPT, NNC, TBB, GW4064, and PD198306; Figure 1) were chosen for further evaluation, because:
(1) previous studies had reported some form of bioactivity for each and (2) their Z-scores in the C.
elegans screen were higher than 2.0, indicating a robust response (Tables 1 and 2).
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Table 1. List of compound names and reported bioactivities.
Compounds Chemical Name Reported Bioactivity
PPT 4,4′,4”-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol
Prevents ovariectomy-induced
weight gain and loss of bone mineral
density, and induces gene expression
in the hypothalamus following






Highly selective T-type calcium
channel blocker. Displays IC50
values of 6.8 and >100 µM for
inhibition of Cav3.1 T-type channels











Selective, non-steroidal farnesoid X





Potent inhibitor of MEK1/2.Highly
selective for MEK.Antihyperalgesic;
blocks static allodynia in the
streptozocin model of neuropathic
pain [14].







2.2. Galleria Mellonella Assays
The five hits were next tested in the G. mellonella–MRSA model to validate their activity in a second
whole-animal infection assay. Maximum tolerated doses (MTDs) were obtained by challenging
uninfected larvae with increasing doses of the compounds (10, 20, and 30 mg/kg). All five compounds
exhibited MTDs of 10 mg/kg (data not shown) and this concentration was used in the infection model.
Larvae were infected with MRSA MW2 (5 × 105 CFU) in the left rear proleg, and after two hours,
the compounds were introduced separately at 10 mg/kg into the right rear proleg and larvae survival
was monitored for 120 h. All compounds prolonged survival relative to untreated controls (Figure 2),
although none were as effective as vancomycin at 10 mg/kg. Untreated larvae showed a median
post-infection survival of only 1 day, while GW4064, NNC, PD198306, and PPT each extended median
survival to 2 days. TBB treatment extended median survival to 3 days.
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inhibit the growth of MW2 and the isolates, with each showing MICs in the range of 2–8 µg/mL. By 
comparison, the MIC of vancomycin was 1 µg/mL against MW2 and 2 µg/mL against other isolates. 
The minimum bactericidal concentration (MBC) of PPT against MW2 was 32 µg/mL, and for NNC, 
TBB, GW4064, and PD198306 it was >64 µg/mL. When tested against ESKAPE pathogens (Table 4), 
good activity (MIC, 2–8 µg/mL) was seen against the Gram-positive bacterium Enterococcus faecium; 
however, poor activity was observed against Gram-negative pathogens except with PD198306, which 
showed modest activity (MIC 32 µg/mL) against Acinetobacter baumanii. 
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NNC 8 >64 
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PD198306 2 >64 
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Fig re 2. Galleria mellonella larvae infected with S.aureus-MW2 were treated with vancomycin
(10 mg/kg) (A) or one of the five compounds (B–F, 10 mg/kg) and survival was monitored for
120 hr. Statistical analyses (Kaplan–Meier survival analysis with log-rank test) ere conducted using
GraphPad Prism version 8 (GraphPad Software, La Jolla, CA, USA).
2.3. Antibacterial Susceptibility
Antibacterial activity of the five compounds was evaluated against MRSA-MW2 (Table 3) and four
additional clinical S. aureus isolates (Table 4). All of the compounds were found to potently inhibit the
growth of MW2 and the isolates, with each showing MICs in the range of 2–8 µg/mL. By comparison,
the MIC of vancomycin was 1 µg/mL against MW2 and 2 µg/mL against other isolates. The minimum
bactericidal concentration (MBC) of PPT against MW2 was 32 µg/mL, and for NNC, TBB, GW4064, and
PD198306 it was >64 µg/mL. When tested against ESKAPE pathogens (Table 4), good activity (MIC,
2–8 µg/mL) was seen against the Gram-positive bacterium Enterococcus faecium; however, poor activity
was observed against Gram-negative pathogens except with PD198306, which showed modest activity
(MIC 32 µg/mL) against Acinetobacter baumanii.
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Table 4. Antibacterial activity of compounds against clinical S. aureus isolates and ESKAPE pathogens.
Clinical S. aureus Isolates and
ESKAPE Pathogens
MIC (µg/mL)
PPT NNC TBB GW4064 PD198306 Vancomycin
BF1 8 4 4 4 2 2
BF2 8 2 4 4 2 2
BF3 8 4 8 8 2 2
BF4 8 4 4 8 2 2
Enterococcus faecium 8 8 4 8 2 4
Klebsiella pneumoniae >64 >64 >64 >64 >64 >64
Acinetobacter baumannii >64 >64 >64 >64 32 >64
Enterobactor aerogens >64 >64 >64 >64 >64 >64
Pseudomonas aeruginosa >64 >64 >64 >64 >64 >64
Time-to-kill assays were used to further probe bactericidal/bacteriostatic properties against MRSA
MW2 (Figure 3). Antibacterial compounds are generally considered bactericidal, if the MBC is no
more than four times higher than the MIC. Bactericidal activity is defined as greater than 3 log10 -fold
decrease in colony forming units, which is equivalent to 99.9% killing of the inoculum. If the MBC is
outside this range, compounds are bacteriostatic [15]. According to these criteria, all five compounds
were bacteriostatic.
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2.4. Membrane Permeabilization
To determine whether the compounds target bacterial membranes, MRSA MW2 was treated with
the compounds and uptake of the membrane-impermeable DNA-binding fluorescent dye Sytox green
was monitored over 1 h (Figure 4). Exposure of cells to the compounds at 64 µg/mL revealed that TBB,
PPT, and NNC caused increases in cellular fluorescence, suggesting that they damage the membrane.
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Compounds GW4064 and PD198306 showed no changes in cellular fluorescence, suggesting that they
do not elicit antibacterial action through effects on membranes.
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Figure 4. Cellular fluorescence of MRSA-MW2 cells treated with sytox green and test compounds
(64 µg/mL) monitored over 1 h. Bithionol (64 µg/mL) was included as positive control.
2.5. Human Red Blood Cell Hemolysis Assays and Cytotoxicity
Serial dilutions of the compounds (2–128 µg/mL) were added to human red blood cells (RBCs) and
monitored for hemolytic activity (Figure 5). NNC and GW4064 showed he olysis at concentrations of
32–64 µg/mL and 8-16 µg/mL, respectively, and PPT caused slight hemolysis at 128 µg/mL. PD198306
and TBB showed no hemolytic activity. Eukaryotic cell cytotoxicity of the compounds was tested using
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method with liver (HepG2),
lung (A549), and gastric (MKN-28) cell lines (Figure 6 and Table 5). All of the compounds were found
to be relatively toxic in these cell-based assays, inhibiting proliferation at concentrations close to their
S. aureus MICs.
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Figure 6. Cytotoxicity: ammalian cells (HepG2, A549, and KN-28) were treated with 2-fold serial
dilutions of compounds and the cytotoxicity was measured after 24 hr.
Table 5. Eukaryotic cell cytotoxicity of compounds (µg/mL).
Compounds HepG2 A549 MKN-28
PPT 8 16 8
NNC 2 16 8
TBB 8 16 16
GW4064 4 16 8
PD198306 2 16 16
2.6. Antibacterial Synergy
The combination of two antibiotics with different modes of action can reduce bacterial resistance
and sometimes even restore clinical efficacy of an antibiotic that has lost effectiveness [16]. The five
compounds were tested against MRSA-MW2 in the presence of five clinical antibiotics from different
classes (i.e., polymyxin B, gentamycin, erythromycin, doxycycline, and oxacillin). Paired combinations
of compounds and their FIC indices are listed in (Table 6). Synergic effects, where the combined
antibacterial activity of the two compounds is greater than the sum of the individual compound
activities, are identified by FIC index ≤ 0.5, antagonism by FIC index > 4.0, and no interaction by
0.5 < FIC index < 4.0. Polymyxin-B showed synergistic activity with NNC and gentamicin synergized
with GW4064. Erythromycin showed synergy with PD198306. Doxycycline and oxacillin both
synergized with TBB, but only doxycycline with PPT. None of the compounds antagonized the activity
of the antibiotics.
Table 6. Fractional Inhibitory Concentration (FIC) Index of test compounds with selected antibiotics
from different classes.
Compounds Polymyxin B Gentamycin Erythromycin Doxycycline Oxacillin
PPT 2.0 1.0 0.75 0.5 1.0
NNC 0.5 0.75 1.0 0.75 2.0
TBB 2.0 1.0 0.625 0.5 0.5
GW4064 0.75 0.5 1.0 2.06 1.0
PD198306 1.0 0.625 0.5 2.0 0.75
3. Discussion
The aim of this study was to characterize the antibacterial properties of five synthetic compounds
with activity against MRSA. The activity of the compounds against MRSA was originally identified
using a C. elegans–MRSA whole-animal infection model. In this study, compound activities were
confirmed at the whole-animal level using the G. mellonella–MRSA model [5]. The G. mellonella infection
model is a quick and inexpensive way to confirm the efficacy of hit compounds against S. aureus
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in vivo [17], but is too cumbersome and labor intensive to implement for large scale screening of
chemical libraries. Hence, we used the G. mellonella model for follow-up validation of C. elegans high
throughput screening hits to enable prioritization of compounds for further characterization.
The five compounds chosen for study here (PPT, NNC, TBB, GW4064, and PD198306) all prolonged
the survival of both C. elegans and G. mellonella infected with MRSA. A literature survey revealed
that although the compounds had reported bioactivities, none had previously been reported to have
antibacterial activity. PPT is described as a subtype-selective ERα agonist. We found that the MIC
of PPT against MRSA-MW2 and four clinical isolates was 8 µg/mL. The compound showed potent
membrane permeabilizing properties and some hemolytic activity in human red blood cells, suggesting
it targets the bacterial membrane. Synergy was observed with PPT and the antibiotic doxycycline.
As a class, pyrazoles show a wide range of biological activities, including antimicrobial, antifungal,
antitubercular, anti-inflammatory, anticancer, antiviral, neuroprotective, and estrogen receptor (ER)
activity [10]. Some pyrazole derivatives have been shown to exhibit activity against both Gram positive
and Gram-negative bacteria and an N-phenyl-1H-pyrazole-4-carboxamide derivative increased the
survival of G. mellonella infected with S. aureus [18]. PPT is a highly hydrophobic pyrazole containing
three phenolic substituents and it is possible that these properties are responsible for the significant
toxicity observed against eukaryotic cells.
NNC is a reported calcium channel blocker [11]. The compound showed a MIC of 8 µg/mL against
MRSA MW2 and was slightly more potent against the other four isolates. As with PPT, NNC appears
to target the bacterial membrane, since it permeabilizes MRSA cells and shows hemolytic activity at
32 µg/mL. It was also found to be cytotoxic against all three eukaryotic cell lines.
TBB is a reported inhibitor of protein kinase 2 (CK2) [12]. The compound showed a MIC between
4–6 µg/mL against MRSA and the clinical isolates and while it appears to be membrane active against
MRSA-MW2, no red blood cell hemolysis was observed. The compound synergized with doxycycline
and oxacillin against MRSA, however, like PPT and NNC, it was also toxic to eukaryotic cell lines at
concentrations around its MIC.
GW4064 is a reported farnesoid X receptor (FXR) agonist [19] that suppresses cell proliferation in
several cancer lines, but not normal cells [20]. The compound showed a MIC of 4–8 µg/mL against the
MRSA strains and synergized with gentamycin. While GW4064 appears not to be membrane active
against MRSA MW2, it showed hemolytic activity at 8 µg/mL and was cytotoxic to eukaryotic cells.
PD198306 is a potent and selective non-ATP competitive inhibitor of MEK1/2 that shows
antihyperalgesic properties [14]. The compound showed the lowest MIC (2 µg/mL) against MRSA
MW2, which was similar for the four other isolates. Its activity was bacteriostatic and the compound
synergized with erythromycin. Importantly, PD198306 does not appear to be membrane active
against MRSA and shows no hemolytic activity, suggesting that its antibacterial action may be more
target-specific than the other compounds. However, PD198306 was also cytotoxic towards the three
eukaryotic cell lines at concentrations around its MIC, potentially reducing its attractiveness for
further study.
In summary, this study demonstrates the utility of the C. elegans/G. mellonella whole animal
dual-screening approach for identifying compounds of interest for study as new agents against MRSA.
The sequential use of two independent model hosts is a powerful tool for prioritizing compounds,
as it confirms that efficacious anti-microbial compounds identified by HTS in C. elegans are indeed
relatively non-toxic at a whole animal level and may warrant further study in vertebrate animals.
Although none of the five compounds exhibited a high level of toxicity at the whole animal level, all five
compounds did inhibit the proliferation of human cells at concentrations approximating the MICs for
MRSA. Despite this, the chemical scaffolds, particularly PD198306, represent good starting points for
traditional medicinal chemistry aimed at decreasing toxicity while maintaining antimicrobial activity.
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4. Materials and Methods
4.1. Hit Compounds
The five compounds: (4,4′,4”-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, PPT; (1S,2S)-2-[2-[[3-
(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-
naphthalenyl cyclopropanecarboxylate dihydrochloride, NNC; 4,5,6,7-tetrabromobenzotriazole, TBB;
3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl] ethenyl]
benzoic acid, GW4064; and N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-[(4-iodo-2-methylphenyl)amino]
benzamide, PD198306) were purchased from Tocris Bioscience at the following levels of purity:
PPT: >99.7%, NNC: >98%, TBB: >99%, GW4064: >97%, and PD198306: 98.8%. These compounds
are members of a set of 185 hits identified previously in a C. elegans–MRSA-MW2 screen of 82,000
synthetic, low molecular weight compounds that block the ability of MRSA to kill nematodes [5,9].
Hits were identified based on Z-scores. Z-scores are calculated from the ratio of alive versus dead
worms after treatment with test compounds and represents the number of standard deviations (SD)
the test compound differs from the mean using the formula Z = (x − µ)/σ; where x is the raw sample
score, µ is the mean of the population and σ is the standard deviation of the population. Samples with
Z > 2σ are considered hits [5].
4.2. Galleria Mellonella Survival Assays
Assays were performed as described previously [21]. Briefly, sixteen randomly selected G. mellonella
larvae (Vanderhorst, Inc., St. Mary’s, OH, USA) between 300–350 mg were used for each test group.
MRSA-MW2 was grown in Tryptic Soy Broth (TSB), washed with phosphate buffered saline (PBS,
pH = 7.4), and diluted to OD600 = 0.3 before inoculation into G. mellonella larvae. A 10-µL inoculum
was injected into the last left proleg using a 10-µL Hamilton syringe. After 2 h, compounds were
administered into the last right proleg and larvae were incubated at 37 ◦C. G.mellonella survival was
monitored for 120 h, and death was confirmed when there was no response. Killing curves and
differences in survival were analyzed by the Kaplan–Meier method using GraphPad Prism version
8 (GraphPad Software, La Jolla, CA, USA). Statistical analysis (Kruskal–Wallis test) was carried out
using the same program.
4.3. Antibacterial Susceptibility Assays
In vitro antibacterial activities were determined using the broth microdilution method [22].
Assays were performed as described in Clinical and Laboratory Standards Institute protocols in triplicate
using cation-adjusted Muller–Hinton broth (Becton Dickinson and Company, Franklin Lakes, NJ, USA)
in 96-well plates with a total assay volume of 100 µL. Two-fold serial dilutions of test compounds were
prepared over the concentration range of 1–64 µg/mL. The bacterial concentration was adjusted to
OD600 = 0.06. MW2 was incubated with the test compounds at 37 ◦C for 18 h, OD600 was measured
and the lowest concentration of each compound that visually inhibited bacterial growth was reported
as the minimal inhibitory concentration (MIC) [23]. A 10 µL aliquot from each well in the MIC assays
was plated onto Muller–Hinton agar (Becton Dickinson and Company, Franklin Lakes, NJ, USA) and
incubated overnight at 37 ◦C. The lowest concentration of compound for which no growth was observed
on agar plates was reported as the minimal bactericidal concentration (MBC).
4.4. Time-To-Kill Assays
Time-to-kill assays were performed as previously described [24]. Briefly, overnight cultures of
MRSA-MW2 were diluted in fresh Tryptic Soy Broth (TSB) to a density of 108 cells/mL and placed into
10 mL tubes (Becton Dickinson and Company, Franklin Lakes, NJ, USA). Test compounds dissolved
in DMSO over the concentration range 4–64 µg/mL were added and the tubes incubated at 37 ◦C.
At periodic intervals, aliquots from each tube were serially diluted with TSB and plated onto tryptic
Antibiotics 2020, 9, 449 10 of 12
soy agar (TSA) (Becton Dickinson and Company, Franklin Lakes, NJ, USA). CFUs were enumerated
after overnight incubation at 37 ◦C. Assays were carried out in triplicate.
4.5. Membrane Permeabilization
Sytox Green (Life Technologies, Needham, MA, USA) membrane permeabilization assays were
performed as previously described [25]. The experiments were carried out in duplicate in 96-well plates.
Cells were grown to log phase and were harvested by centrifuging at 3700× g for 5 min. The cells were
washed twice with PBS and resuspended to OD600 = 0.2, following which 5 µM Sytox green was added
to the cells and the bacteria-dye mixture were incubated in the dark for 30 mins.
Cell suspensions (50 µL) were added to 50 µL of test compounds (64 µg/mL in PBS) and
fluorescence intensity was measured (excitation 485 nm, emission 530 nm) periodically over 60 min.
Bithionol, which our laboratory previously showed permeabilizes MRSA [26], was used as a positive
control. Membrane damage caused by compounds was indicated by increases in cellular fluorescence
caused by enhanced permeability of the DNA staining, membrane-impermeable dye.
4.6. Human Red Blood Cell (RBC) Hemolysis Assays
Human erythrocytes (Rockland Immunochemicals, Limerick, PA, USA) were used to measure
hemolytic activity of the compounds, as previously described [27]. Human erythrocytes (4% in PBS,
50 µL) were added to 50 µL of test compounds serially diluted in PBS, with Triton X-100 and PBS
serving as a positive and negative controls, respectively. After incubation at 37 ◦C for 1 hr, the plates
were centrifuged at 500× g for 5 min and 50 µL of the supernatant was transferred from each well
to a second 96-well plate and the absorbance at 540 nm was measured. Assays were carried out
in triplicate.
4.7. Cytotoxicity Assays
Mammalian cell lines HepG2 (hepatic cells), A549 (epithelial cells), and MKN-28 (gastric
cells) were used to measure the anti-proliferative properties of test compounds, as described
elsewhere [28]. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Waltham,
MA, USA) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco, Waltham, MA, USA) and
1% penicillin/streptomycin (Gibco, Waltham, MA, USA) and maintained at 37 ◦C in 5% CO2.
After harvesting, the cells were suspended in DMEM and 100 µL was added to the wells of 96-well
plates. The test compounds were serially diluted in serum and antibiotic free DMEM, added to the
monolayer of cells, and incubated at 37 ◦C in 5% CO2 for 24 hr. Percentage survival was calculated by
comparison to DMSO-treated vehicle controls. Assays were carried out in triplicate.
4.8. Checkboard Assays
Antibacterial synergy for combinations of the compounds with each other and with clinical
antibiotics (doxycycline, gentamicin, polymyxin-B, oxacillin, and erythromycin) was measured using
checkerboard assays. In short, Cultures of MRSA-MW2 were adjusted to OD600 = 0.06 and one
compound was arrayed horizontally and other vertically in 96 well plates. The assays were carried out
in triplicate, exactly as described for the antibacterial susceptibility assays. The inhibitory effects of
compound combinations were evaluated using the Fractional Inhibitory Concentration (FIC) index,
derived from the formula:
FIC index = FICA + FICB = [A]/MICA + [B]/MICB
MIC of substance A tested in combination /MIC of substance A tested alone + MIC of substance
B tested in combination/MIC of substance B tested alone. Synergy is indicated when FIC ≤ 0.5,
indifference when 0.5 ≤ FIC ≤ 4, and antagonism when FIC > 4. Experiments were performed in
duplicate and report the average FIC index [29].
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